Much more than a ‘party drug’

Update: 2023-06-07

Description

Psilocybin, MDMA or LSD might associate with party drugs but their therapeutic value is being discovered worldwide. Ian Roullier took part in two clinical trials that looked at the effects of psilocybin on depression. Through his personal experience, Roullier shares his insights on psychedelic-assisted therapy, its potential value to patients and what is needed to boost research in this field.

Comments

In Channel

Understanding vaccine hesitancy in Europe

2023-07-2612:20

AI: at the Interface of computer science and Medicine

2023-07-1932:33

European Health Data Space on the Parliament's Plate

2023-07-1225:54

Balancing patients' privacy and health data's potential

2023-07-0520:29

The challenge of guaranteeing access to healthcare to all Ukrainian refugees

2023-06-2819:08

A closer look at Europe's fertility challenge

2023-06-2110:39

Endocrine Disrupting Chemicals: a silent threat for children's development

2023-06-1414:07

Much more than a ‘party drug’

2023-06-0735:43

The need to phase out tobacco farming

2023-05-3116:47

Mental health matters in the Parliament

2023-05-2414:09

The Importance of early testing

2023-05-1721:26

Discovering Monderna's new landscape for vaccines in Europe

2023-05-1011:26

Unwrapping the new pharmaceutical legislation

2023-05-0313:51

Out of REACH

2023-04-2611:11

Fact checking The Whale’s obesity portrayal

2023-04-1912:08

The crime of passing the pill

2023-04-0516:54

Ukraine's fight against TB

2023-03-2920:00

The EU rules for sperm in SoHo

2023-03-2212:00

Unboxing the EU’s medical devices rules

2023-03-1515:11

Talking women's health with Kyriakides

2023-03-0816:31

00:00

Much more than a ‘party drug’

#box-pro-ellipsis-17604135352876{-webkit-line-clamp:2;}Much more than a ‘party drug’

Much more than a ‘party drug’

Euractiv

Much more than a ‘party drug’